Research ArticleOriginal Article
Open Access

COVID-19 vaccine in hemodialysis patients

Time for a boost

Waleed H. Mahallawi
Saudi Medical Journal September 2023, 44 (9) 882-888; DOI: https://doi.org/10.15537/smj.2023.44.9.20230285

References

  1. 1.↵
    1. Chawki S,
    2. Buchard A,
    3. Sakhi H,
    4. Dardim K,
    5. El Sakhawi K,
    6. Chawki M, et al.
    Treatment impact on COVID-19 evolution in hemodialysis patients. Kidney Int 2020; 98: 1053–1054.
    OpenUrlPubMed
  2. 2.↵
    1. Taji L,
    2. Thomas D,
    3. Oliver MJ,
    4. Ip J,
    5. Tang Y,
    6. Yeung A, et al.
    COVID-19 in patients undergoing long-term dialysis in Ontario. CMAJ 2021; 193: E278–E284.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Mousa D,
    2. Alharbi A,
    3. Helal I,
    4. Al-Homrany M,
    5. Alhujaili F,
    6. Alhweish A, et al.
    Prevalence and associated factors of chronic kidney disease among relatives of hemodialysis patients in Saudi Arabia. Kidney Int Rep 2021; 6: 817–820.
    OpenUrl
  4. 4.↵
    1. Krueger KM,
    2. Ison MG,
    3. Ghossein C.
    Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation. Am J Kidney Dis 2020; 75: 417–425.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Mahallawi WH,
    2. Alharbi WA,
    3. Aloufi SA,
    4. Ibrahim NA,
    5. Abdelrahman MM,
    6. Alhomayeed BA, et al.
    Declined humoral immunity of kidney transplant recipients to SARS-CoV-2 vaccines. Infect Drug Resist 2023; 16: 2829–2840.
    OpenUrl
  6. 6.↵
    1. El Karoui K,
    2. De Vriese AS.
    COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment. Kidney Int 2022; 101: 883–894.
    OpenUrl
  7. 7.
    1. Kolb T,
    2. Fischer S,
    3. Müller L,
    4. Lübke N,
    5. Hillebrandt J,
    6. Andrée M, et al.
    Impaired immune response to SARS-CoV-2 vaccination in dialysis patients and in kidney transplant recipients. Kidney360 2021; 2: 1491–1498.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Chen JJ,
    2. Lee TH,
    3. Tian YC,
    4. Lee CC,
    5. Fan PC,
    6. Chang CH.
    Immunogenicity rates after SARS-CoV-2 vaccination in people with end-stage kidney disease: a systematic review and meta-analysis. JAMA Netw Open 2021; 4: e2131749.
    OpenUrl
  9. 9.↵
    1. Patel R,
    2. Kaki M,
    3. Potluri VS,
    4. Kahar P,
    5. Khanna D.
    A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna, and Johnson & Johnson. Hum Vaccin Immunother 2022; 18: 2002083.
    OpenUrlPubMed
  10. 10.↵
    1. Grupper A,
    2. Sharon N,
    3. Finn T,
    4. Cohen R,
    5. Israel M,
    6. Agbaria A, et al.
    Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol 2021; 16: 1037–1042.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Yanay NB,
    2. Freiman S,
    3. Shapira M,
    4. Wishahi S,
    5. Hamze M,
    6. Elhaj M, et al.
    Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients. Kidney Int 2021; 99: 1496–1498.
    OpenUrlCrossRef
  12. 12.↵
    1. Sakhi H,
    2. Dahmane D,
    3. Attias P,
    4. Kofman T,
    5. Bouvier M,
    6. Lapidus N, et al.
    Kinetics of anti-SARS-CoV-2 IgG antibodies in hemodialysis patients 6 months after infection. J Am Soc Nephrol 2021; 32: 1033–1036.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Munro APS,
    2. Janani L,
    3. Cornelius V,
    4. Aley PK,
    5. Babbage G,
    6. Baxter D, et al.
    Safety and immunogenicity of 7 COVID-19 vaccines as a 3rd dose (booster) following 2 doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, and phase 2 trial. Lancet 2021; 398: 2258–2276.
    OpenUrlPubMed
  14. 14.↵
    1. Zhou P,
    2. Yang XL,
    3. Wang XG,
    4. Hu B,
    5. Zhang L,
    6. Zhang W, et al.
    A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579: 270–273.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Metcalf CJ,
    2. Farrar J,
    3. Cutts FT,
    4. Basta NE,
    5. Graham AL,
    6. Lessler J, et al.
    Use of serological surveys to generate key insights into the changing global landscape of infectious disease. Lancet 2016; 388: 728–730.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Mahallawi WH.
    A serological assay to detect human SARS-CoV-2 antibodies. J Taibah Univ Med Sci 2021; 16: 57–62.
    OpenUrl
  17. 17.↵
    1. Htay H,
    2. Foo MWY,
    3. Jayaballa M,
    4. Johnson DW,
    5. Oei EL,
    6. Tan BH, et al.
    Clinical features, management and outcomes of peritoneal dialysis patients during Delta and Omicron waves of COVID-19 infections. Int Urol Nephrol 2023; 55: 2075–2081.
    OpenUrl
  18. 18.↵
    1. Sanhueza ME,
    2. San Martín P,
    3. Brantes L,
    4. Caro S,
    5. Carrasco G,
    6. Machuca E.
    Efficacy of vaccination against the SARS-CoV-2 virus in patients with chronic kidney disease on hemodialysis. Hum Vaccin Immunother 2023; 19: 2173904.
    OpenUrl
  19. 19.
    1. Taheri S.
    Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: systematic review and meta-analysis. Int Urol Nephrol 2023; 55: 791–802.
    OpenUrl
  20. 20.↵
    1. Mahallawi WH,
    2. Fakher MH,
    3. Alsarani MA,
    4. Aljohani RH,
    5. Al-Mutabgani SA,
    6. Ibrahim NA.
    A single dose of SARS-CoV-2 vaccine primes a srong humoral immune response in COVID-19-recovered patients. Viral Immunol 2022; 35: 122–128.
    OpenUrl
  21. 21.↵
    1. Khoury DS,
    2. Cromer D,
    3. Reynaldi A,
    4. Schlub TE,
    5. Wheatley AK,
    6. Juno JA, et al.
    Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021; 27: 1205–1211.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Chan L,
    2. Fuca N,
    3. Zeldis E,
    4. Campbell KN,
    5. Shaikh A.
    Antibody response to mRNA-1273 SARS-CoV-2 vaccine in hemodialysis patients with and without prior COVID-19. Clin J Am Soc Nephrol 2021; 16: 1258–1260.
    OpenUrlFREE Full Text
  23. 23.↵
    1. Babel N,
    2. Hugo C,
    3. Westhoff TH.
    Vaccination in patients with kidney failure: lessons from COVID-19. Nat Rev Nephrol 2022; 18: 708–723.
    OpenUrl
  24. 24.↵
    1. Mahallawi WH,
    2. Ibrahim NA,
    3. Mumena WA.
    Effectiveness of COVID-19 vaccines in patients under maintenance hemodialysis. Risk Manag Healthc Policy 2021; 14: 5081–5088.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Dekervel M,
    2. Henry N,
    3. Torreggiani M,
    4. Pouteau LM,
    5. Imiela JP,
    6. Mellaza C, et al.
    Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis. Clin Kidney J 2021; 14: 2349–2355.
    OpenUrl
  26. 26.↵
    1. Longlune N,
    2. Nogier MB,
    3. Miedougé M,
    4. Gabilan C,
    5. Cartou C,
    6. Seigneuric B, et al.
    High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. Nephrol Dial Transplant 2021; 36: 1704–1709.
    OpenUrlPubMed
  27. 27.↵
    1. Bobrovitz N,
    2. Ware H,
    3. Ma X,
    4. Li Z,
    5. Hosseini R,
    6. Cao C, et al.
    Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis 2023; 23: 556–567.
    OpenUrlCrossRef
  28. 28.
    1. Gazit S,
    2. Shlezinger R,
    3. Perez G,
    4. Lotan R,
    5. Peretz A,
    6. Ben-Tov A, et al.
    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naturally acquired immunity versus vaccine-induced immunity, reinfections versus breakthrough infections: a retrospective cohort study. Clin Infect Dis 2022; 75: e545–e551.
    OpenUrl
  29. 29.↵
    1. Larkin H.
    Hybrid immunity more protective than prior SARS-CoV-2 infection alone. JAMA 2023; 329: 531.
    OpenUrl
  30. 30.↵
    1. Notarte KI,
    2. Catahay JA,
    3. Velasco JV,
    4. Pastrana A,
    5. Ver AT,
    6. Pangilinan FC, et al.
    Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. EClinicalMedicine 2022; 53: 101624.
    OpenUrl
  31. 31.↵
    1. Buckner CM,
    2. Kardava L,
    3. El Merhebi O,
    4. Narpala SR,
    5. Serebryannyy L,
    6. Lin BC, et al.
    Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses. Cell 2022; 185: 4333–4346.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords